SGO Issues Apr. 7, 2016
FDA allows marketing of containment system for morcellators
Precision medicine special section in April journal
SGO Annual Meeting breaks attendance record again
On the Scene 2016 Annual Meeting: ConnectEd
Winner announced for #SGOHAWAII contest
Responding to questions about talc and cancer
Cancer and Family History: Using Genomics for Prevention
The U.S. Food and Drug Administration today permitted the marketing of PneumoLiner, the first tissue containment system for use with certain laparoscopic power morcellators to isolate uterine tissue that is not suspected to contain cancer. Although the device is an effective tissue containment system, the FDA is requiring the manufacturer to warn patients and health care providers that PneumoLiner has not been proven to reduce the risk of spreading cancer during these procedures.
The April 2016 issue of Gynecologic Oncology has a special section on the Use of Precision Medicine in the Management of Gynecologic Cancers, with guest editors Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center in Houston and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute in Boston. In their editorial, Dr. Coleman and Dr. Matulonis stated that they invited investigators to submit manuscripts on research related to the study of precision medicine “and its implications on early detection and prevention, etiology, treatment and prognosis.”
The initial announcement for this special edition of Gynecologic Oncology also coincided with the White House’s Precision Medicine initiative in 2015.
According to the editorial, “Articles have been grouped into four categories based on the role Precision Medicine is informing patient management, prediction of response to treatment, development of novel therapeutic strategies and descriptions of novel genetic pathways, or classifications for gynecologic cancers.”
Last month SGO’s Annual Meeting on Women’s Cancer broke an attendance record for the second year in a row with 2,156 attendees, 9.5% (or 99 registrants) higher than the 2015 meeting. Included in the 2016 number were 387 attendees from 45 different countries. The event also had the highest number of exhibitors (50) since 2007. The 2017 Annual Meeting will be March 12-15, in National Harbor, MD (near Washington, DC).
SGO Education Committee member Josh Cohen, MD, from the University of California at Los Angeles, provides a preview of recorded sessions from the 47th Annual Meeting on Women’s Cancer that will be available in the weeks to come. Annual Meeting attendees will soon receive an email directing them to recordings that are available through the Society’s e-learning platform, SGO Connect Ed.
Jacek Sznurkowski, MD, PhD, MBA, a gynecologic oncologist from the Medical University of Gdańsk, Poland, has won a free registration to SGO’s 50th Annual Meeting on Women’s Cancer in Honolulu, HI, March 16-19, 2019. Contest participants took selfie photos at the SGO/FWC booth in the Exhibit Hall during the 2016 meeting in San Diego and posted them to Twitter or Facebook with the hashtag #SGOHAWAII and the winner was randomly selected.
A recent court ruling ordered Johnson & Johnson to pay $72 million to the family of a woman who blamed her fatal ovarian cancer on the company’s talcum powder. The American Cancer Society provides a science-based summary of talcum powder and cancer issue and the Ovarian Cancer National Alliance has a brief statement in its FAQs about ovarian cancer.
The CDC is hosting an online Public Health Grand Rounds on Cancer and Family History: Using Genomics for Prevention on Tuesday, April 19, at 1:00 p.m. ET with Lisa Richardson, MD, MPH, Director, CDC Division of Cancer Prevention and Control; Debra Duquette, MS, CGC, Genomics Coordinator, Michigan Department of Health and Human Services; Lindsay Avner, Founder and CEO, Bright Pink and Muin Khoury, MD, PhD, Director, CDC Office of Public Health Genomics.